Brilliant blue G attenuates neuro‑inflammation via regulating MAPKs and NF‑&kappa;B signaling pathways in lipopolysaccharide‑induced BV2 microglia cells

Wang,Wei; Huang,Feiran; Jiang,Weifeng; Wang,Weiwei; Xiang,Jie

doi:10.3892/etm.2020.9244

Brilliant blue G attenuates neuro‑inflammation via regulating MAPKs and NF‑κB signaling pathways in lipopolysaccharide‑induced BV2 microglia cells

Authors:
- Wei Wang
- Feiran Huang
- Weifeng Jiang
- Weiwei Wang
- Jie Xiang
View Affiliations

Affiliations: Department of Rehabilitation, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China, Department of Neurology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China, Department of Neurology, The Second People's Hospital of Quzhou, Quzhou, Zhejiang, 324000, P.R. China
Published online on: September 18, 2020 https://doi.org/10.3892/etm.2020.9244
Article Number: 116
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that the P2X purinoceptor 7 (P2X7) receptor (P2X7R) serves a critical role in regulating the inflammatory response of various diseases in the central nervous system. The anti‑inﬂammatory effect of brilliant blue G (BBG), a specific antagonist of the P2X7R, remains unclear in lipopolysaccharide (LPS)‑induced BV‑2 cells. The present study suggested that BBG attenuated the neuroinﬂammatory response; the protein levels of inducible oxide synthase and cyclooxygenase‑2, and the mRNA and secretion levels of pro‑inflammatory cytokines including interleukin (IL)‑16, IL‑1β and tumor necrosis factor‑α (TNF‑α), were all decreased in LPS‑induced BV2 cells. BBG inhibited the activation of MAPKs by inhibiting the phosphorylation of p38 mitogen‑activated protein kinase, c‑Jun N‑terminal kinase and extracellular signal‑regulated kinase. Notably, transcription factor p65 nuclear translocation was also inhibited, thereby leading to the inactivation of NF‑κB. The inhibitory effects of BBG on MAPKs and NF‑κB were additionally enhanced through the application of MAPK and NF‑κB inhibitors. Taken together, the results demonstrated that BBG contributed to the suppression of the inflammatory effects in LPS‑induced BV2 cells via the inhibition of NF‑κB and MAPKs signaling pathways.

View Figures

View References

1	Hanamsagar R and Bilbo SD: Sex differences in neurodevelopmental and neurodegenerative disorders: Focus on microglial function and neuroinflammation during development. J Steroid Biochem Mol Biol. 160:127–133. 2016.PubMed/NCBI View Article : Google Scholar
2	Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al: Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14:388–405. 2015.PubMed/NCBI View Article : Google Scholar
3	Colonna M and Butovsky O: Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 35:441–468. 2017.PubMed/NCBI View Article : Google Scholar
4	Biber K, Moller T, Boddeke E and Prinz M: Central nervous system myeloid cells as drug targets: current status and translational challenges. Nat Rev Drug Discov. 15:110–124. 2016.PubMed/NCBI View Article : Google Scholar
5	Liu RP, Zou M, Wang JY, Zhu JJ, Lai JM, Zhou LL, Chen SF, Zhang X and Zhu JH: Paroxetine ameliorates lipopolysaccharide-induced microglia activation via differential regulation of MAPK signaling. J Neuroinflammation. 11(47)2014.PubMed/NCBI View Article : Google Scholar
6	Yoshida Y, Yoshimi R, Yoshii H, Kim D, Dey A, Xiong H, Munasinghe J, Yazawa I, O’Donovan MJ, Maximova OA, et al: The transcription factor IRF8 activates integrin-mediated TGF-β signaling and promotes neuroinflammation. Immunity. 40:187–198. 2014.PubMed/NCBI View Article : Google Scholar
7	Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U and Lucius R: Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation. 7(30)2010.PubMed/NCBI View Article : Google Scholar
8	Sarkar FH, Li Y, Wang Z and Kong D: NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol. 27:293–319. 2008.PubMed/NCBI View Article : Google Scholar
9	Lai JL, Liu YH, Liu C, Qi MP, Liu RN, Zhu XF, Zhou QG, Chen YY, Guo AZ and Hu CM: Indirubin inhibits LPS-induced inflammation via TLR4 abrogation mediated by the NF-κB and MAPK signaling pathways. Inflammation. 40:1–12. 2017.PubMed/NCBI View Article : Google Scholar
10	Chew J, Biswas S, Shreeram S, Humaidi M, Wong ET, Dhillion MK, Teo H, Hazra A, Fang CC, López-Collazo E, et al: WIP1 phosphatase is a negative regulator of NF-kappaB signalling. Nat Cell Biol. 11:659–666. 2009.PubMed/NCBI View Article : Google Scholar
11	Zhao H, Wang SL, Qian L, Jin JL, Li H, Xu Y and Zhu XL: Diammonium glycyrrhizinate attenuates Aβ(1-42)-induced neuroinflammation and regulates MAPK and NF-κB pathways in vitro and in vivo. CNS Neurosci Ther. 19:117–124. 2013.PubMed/NCBI View Article : Google Scholar
12	Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Serrano JR, Robinson GO, Anderson E, Colonna M and Holtzman DM: TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci USA. 114:11524–11529. 2017.PubMed/NCBI View Article : Google Scholar
13	Volonte C, Apolloni S, Skaper SD and Burnstock G: P2X7 receptors: channels, pores and more. CNS Neurol Disord Drug Targets. 11:705–721. 2012.PubMed/NCBI View Article : Google Scholar
14	Chen S, Ma Q, Krafft PR, Chen Y, Tang J, Zhang J and Zhang JH: P2X7 receptor antagonism inhibits p38 mitogen-activated protein kinase activation and ameliorates neuronal apoptosis after subarachnoid hemorrhage in rats. Crit Care Med. 41:e466–e474. 2013.PubMed/NCBI View Article : Google Scholar
15	Skaper SD, Debetto P and Giusti P: The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J. 24:337–345. 2010.PubMed/NCBI View Article : Google Scholar
16	Zhao H, Pan P, Yang Y, Ge H, Chen W, Qu J, Shi J, Cui G, Liu X, Feng H and Chen Y: Endogenous hydrogen sulphide attenuates NLRP3 inflammasome-mediated neuroinflammation by suppressing the P2X7 receptor after intracerebral haemorrhage in rats. J Neuroinflammation. 14(163)2017.PubMed/NCBI View Article : Google Scholar
17	Wang XH, Xie X, Luo XG, Shang H and He ZY: Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson's disease. Mol Med Rep. 15:768–776. 2017.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	Rahimifard M, Maqbool F, Moeini-Nodeh S, Niaz K, Abdollahi M, Braidy N, Nabavi SM and Nabavi SF: Targeting the TLR4 signaling pathway by polyphenols: A novel therapeutic strategy for neuroinflammation. Ageing Res Rev. 36:11–19. 2017.PubMed/NCBI View Article : Google Scholar
20	Baima ET, Guzova JA, Mathialagan S, Nagiec EE, Hardy MM, Song LR, Bonar SL, Weinberg RA, Selness SR, Woodard SS, et al: Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-kappaB essential modulator binding domain peptides. J Biol Chem. 285:13498–13506. 2010.PubMed/NCBI View Article : Google Scholar
21	Le W, Rowe D, Xie W, Ortiz I, He Y and Appel SH: Microglial activation and dopaminergic cell injury: An in vitro model relevant to Parkinson's disease. J Neurosci. 21:8447–8455. 2001.PubMed/NCBI View Article : Google Scholar
22	Glass CK, Saijo K, Winner B, Marchetto MC and Gage FH: Mechanisms underlying inflammation in neurodegeneration. Cell. 140:918–934. 2010.PubMed/NCBI View Article : Google Scholar
23	Yu Q, Guo Z, Liu X, Ouyang Q, He C, Burnstock G, Yuan H and Xiang Z: Block of P2X7 receptors could partly reverse the delayed neuronal death in area CA1 of the hippocampus after transient global cerebral ischemia. Purinergic Signal. 9:663–675. 2013.PubMed/NCBI View Article : Google Scholar
24	Petes C, Wynick C, Guzzo C, Mehta D, Logan S, Banfield BW, Basta S, Cooper A and Gee K: IL-27 enhances LPS-induced IL-1β in human monocytes and murine macrophages. J Leukoc Biol. 102:83–94. 2017.PubMed/NCBI View Article : Google Scholar
25	Cesario A, Rocca B and Rutella S: The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr Med Chem. 18:2263–2271. 2011.PubMed/NCBI View Article : Google Scholar
26	Cai B, Seong KJ, Bae SW, Chun C, Kim WJ and Jung JY: A synthetic diosgenin primary amine derivative attenuates LPS-stimulated inflammation via inhibition of NF-kappaB and JNK MAPK signaling in microglial BV2 cells. Int Immunopharmacol. 61:204–214. 2018.PubMed/NCBI View Article : Google Scholar
27	Stokes JA, Cheung J, Eddinger K, Corr M and Yaksh TL: Toll-like receptor signaling adapter proteins govern spread of neuropathic pain and recovery following nerve injury in male mice. J Neuroinflammation. 10(148)2013.PubMed/NCBI View Article : Google Scholar
28	Mattson MP, Culmsee C, Yu Z and Camandola S: Roles of nuclear factor kappaB in neuronal survival and plasticity. J Neurochem. 74:443–456. 2000.PubMed/NCBI View Article : Google Scholar
29	Wan P, Liu X, Xiong Y, Ren Y, Chen J, Lu N, Guo Y and Bai A: Extracellular ATP mediates inflammatory responses in colitis via P2 x7 receptor signaling. Sci Rep. 6(19108)2016.PubMed/NCBI View Article : Google Scholar
30	Hu H, Yang B, Li Y, Zhang S and Li Z: Blocking of the P2X7 receptor inhibits the activation of the MMP-13 and NF-kappaB pathways in the cartilage tissue of rats with osteoarthritis. Int J Mol Med. 38:1922–1932. 2016.PubMed/NCBI View Article : Google Scholar
31	Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802:396–405. 2010.PubMed/NCBI View Article : Google Scholar
32	Chu K, Yin B, Wang J, Peng G, Liang H, Xu Z, Du Y, Fang M, Xia Q and Luo B: Inhibition of P2X7 receptor ameliorates transient global cerebral ischemia/reperfusion injury via modulating inflammatory responses in the rat hippocampus. J Neuroinflammation. 9(69)2012.PubMed/NCBI View Article : Google Scholar
33	Papp L, Vizi ES and Sperlagh B: P2X7 receptor mediated phosphorylation of p38MAP kinase in the hippocampus. Biochem Biophys Res Commun. 355:568–574. 2007.PubMed/NCBI View Article : Google Scholar
34	Wen Z, Mei B, Li H, Dou Y, Tian X, Shen M and Chen G: P2X7 participates in intracerebral hemorrhage-induced secondary brain injury in rats via MAPKs signaling pathways. Neurochem Res. 42:2372–2383. 2017.PubMed/NCBI View Article : Google Scholar
35	Kumar S, Mishra A and Krishnamurthy S: Purinergic antagonism prevents mitochondrial dysfunction and behavioral deficits associated with dopaminergic toxicity induced by 6-OHDA in rats. Neurochem Res. 42:3414–3430. 2017.PubMed/NCBI View Article : Google Scholar
36	Wu F, Wang Z, Gu JH, Ge JB, Liang ZQ and Qin ZH: p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease. Neurochem Int. 63:133–140. 2013.PubMed/NCBI View Article : Google Scholar